Opinion|Videos|November 20, 2026

Reducing Bronchiectasis Mortality: Treatment Advances and What's Next

With a first-in-class treatment now available and awareness slowly spreading, the field sees a genuine opportunity to change bronchiectasis morbidity and mortality over the next decade.

In "Reducing Bronchiectasis Mortality: Treatment Advances and What's Next," Dr. Swenson closes this conversation by outlining what has driven progress against bronchiectasis mortality and what still needs to change.

Dr. Swenson ranks awareness and education as the top priorities for reducing bronchiectasis morbidity and mortality, alongside the direct expenditures the panel discussed earlier. He credits the founding of the Bronchiectasis and NTM Association with driving substantial progress in both patient and provider education, helping more clinicians recognize and diagnose the disease. Until last year's FDA approval of the first DPP1 inhibitor, Dr. Swenson explains, treatment relied almost entirely on a one-size-fits-all approach built around airway clearance techniques to reduce mucus and infection risk. That approach remains a mainstay, he notes, but clinicians now also emphasize regular aerobic and resistance exercise and maintaining a healthy body mass index, since many patients become cachexic and lose significant weight, compounding sarcopenia risk after age 65.

Dr. Swenson highlights the newly available DPP1 inhibitor as a meaningful advance, citing Phase 2 and Phase 3 data showing a significant reduction in exacerbation rates. Because exacerbations drive disease progression and severity, he argues, any therapy that reduces them should meaningfully improve morbidity and mortality over time. Looking ahead, Dr. Swenson expresses genuine optimism that bronchiectasis awareness will keep spreading across pulmonary specialists, primary care providers, advanced practice clinicians, and nursing staff, echoing how COPD and asthma awareness grew in earlier decades. He also calls for greater awareness among payers, urging them to recognize that bronchiectasis is distinct from COPD and asthma and that its exacerbations drive comparable readmissions and mortality. Prioritizing coverage for newer, targeted therapies and treatable-trait-based care, he says, could meaningfully alter the disease's course over the next five to ten years.


Related to this article